Business Description
Hikma Pharmaceuticals PLC
ISIN : US4312881091
Share Class Description:
HKMPY: ADRTotal Employee Number:
9,603Compare
Compare
Traded in other countries / regions
HIK.UKHKMPF.USAH5P.GermanyHIK.United Arab EmiratesHIKN.Mexico IPO Date
2009-12-23Description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.78 | |||||
Debt-to-EBITDA | 2.27 | |||||
Interest Coverage | 6.19 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.7 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.9 | |||||
3-Year EBITDA Growth Rate | 17 | |||||
3-Year EPS without NRI Growth Rate | 4.5 | |||||
3-Year FCF Growth Rate | -32.8 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.66 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.99 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.25 | |||||
9-Day RSI | 30.93 | |||||
14-Day RSI | 43.18 | |||||
3-1 Month Momentum % | 11.03 | |||||
6-1 Month Momentum % | 21.61 | |||||
12-1 Month Momentum % | -12.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.98 | |||||
Quick Ratio | 1.13 | |||||
Cash Ratio | 0.21 | |||||
Days Inventory | 211.25 | |||||
Days Sales Outstanding | 112.05 | |||||
Days Payable | 103.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.96 | |||||
Dividend Payout Ratio | 0.36 | |||||
3-Year Dividend Growth Rate | 13.2 | |||||
Forward Dividend Yield % | 3.96 | |||||
5-Year Yield-on-Cost % | 7.62 | |||||
Shareholder Yield % | 1.37 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.61 | |||||
Operating Margin % | 18.11 | |||||
Net Margin % | 11.32 | |||||
EBITDA Margin % | 25.27 | |||||
FCF Margin % | 5.59 | |||||
OCF Margin % | 14.3 | |||||
ROE % | 15.25 | |||||
ROA % | 6.84 | |||||
ROIC % | 9.98 | |||||
3-Year ROIIC % | 8.25 | |||||
ROC (Joel Greenblatt) % | 24.12 | |||||
ROCE % | 15.14 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.35 | |||||
Forward PE Ratio | 8.98 | |||||
PE Ratio without NRI | 9.41 | |||||
Shiller PE Ratio | 20.4 | |||||
Price-to-Owner-Earnings | 21.11 | |||||
PEG Ratio | 2.24 | |||||
PS Ratio | 1.39 | |||||
PB Ratio | 1.8 | |||||
Price-to-Tangible-Book | 3.26 | |||||
Price-to-Free-Cash-Flow | 25.04 | |||||
Price-to-Operating-Cash-Flow | 9.76 | |||||
EV-to-EBIT | 10.17 | |||||
EV-to-Forward-EBIT | 14.33 | |||||
EV-to-EBITDA | 7.19 | |||||
EV-to-Forward-EBITDA | 6.34 | |||||
EV-to-Revenue | 1.82 | |||||
EV-to-Forward-Revenue | 1.71 | |||||
EV-to-FCF | 32.52 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 0.83 | |||||
Price-to-DCF (Earnings Based) | 0.71 | |||||
Price-to-DCF (FCF Based) | 2.18 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Price-to-Graham-Number | 1.16 | |||||
Earnings Yield (Greenblatt) % | 9.83 | |||||
FCF Yield % | 4.22 | |||||
Forward Rate of Return (Yacktman) % | 10.81 |
Hikma Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hikma Pharmaceuticals PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 09:30 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 177 days | ||
| USD 0.760000 Cash Dividend | 2026-08-17 | 45.36 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 43.50 (+0.00%) | ||
| General meeting for 2025 | 2026-04-23 10:00 | 37.30 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-23 08:30 | 37.30 (+0.00%) | ||
| USD 0.960000 Cash Dividend | 2026-03-20 | 34.20 (+1.91%) | ||
| Annual report for 2025 | 2026-03-18 | 34.64 (-0.33%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 09:30 | 45.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 45.06 (+0.00%) |
Show
Entries
Press Release
Articles on Hikma Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers